| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Enanta Pharma (NASDAQ:ENTA) reported its Q1 earnings results on Wednesday, February 7, 2024 at 04:01 PM.
Here's what investors need to know about the announcement.
Enanta Pharma missed estimated earnings by 32.77%, reporting an EPS of $-1.58 versus an estimate of $-1.19.
Revenue was down $5.58 million from the same period last year.
Last quarter the company beat on EPS by $0.67 which was followed by a 11.52% increase in the share price the next day.
Here's a look at Enanta Pharma's past performance:
| Quarter | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|
| EPS Estimate | -2 | -2.33 | -1.98 | -1.59 |
| EPS Actual | -1.33 | -1.86 | -1.79 | -1.39 |
| Revenue Estimate | 17.50M | 18.06M | 19.18M | 22.57M |
| Revenue Actual | 18.93M | 18.89M | 17.80M | 23.59M |
To track all earnings releases for Enanta Pharma visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ENTA
